A correlation of FTIR spectra derived from prostate cancer biopsies with gleason grade and tumour stage.
Authors
Gazi, EhsanBaker, Matthew J
Dwyer, John
Lockyer, Nicholas P
Gardner, Peter
Shanks, Jonathan H
Reeve, Roy S
Hart, Claire A
Clarke, Noel W
Brown, Michael D
Affiliation
School of Chemical Engineering and Analytical Science, University of Manchester, Manchester, UK. EGazi@picr.man.ac.ukIssue Date
2006-10
Metadata
Show full item recordAbstract
OBJECTIVES: We introduce biochemistry as a second dimension to Gleason grading, using Fourier transform infrared (FTIR) microspectroscopy. For the first time, we correlate FTIR spectra derived from prostate cancer (pCA) tissue with Gleason score and the clinical stage of the tumour at time of biopsy. METHODS: Serial sections from paraffin-embedded pCA tissue were collected. One was stained with hematoxylin and eosin and Gleason scored; FTIR spectra were collected from malignant locations using a second unstained section. FTIR spectra, representing different Gleason grades, were used to construct a diagnostic classifier for pCA using linear discriminant analysis (LDA). This model was blind tested using 383 IR spectra from 36 biopsies. RESULTS: Using a three-band Gleason criteria, we obtained sensitivity of > or =70% for the FTIR-LDA model to predict Gleason <7,=7, and >7, with specificities of > or =81%. Using a threshold of Gleason/FTIR-LDA score of > or =8, we obtained a sensitivity and specificity of 71% and 67%, respectively, for the correlation with metastatic tumours using the FTIR-LDA system and 85% and 63%, respectively, for the correlation of metastatic tumours using the Gleason system. CONCLUSIONS: There is a correlation between tissue architecture using Gleason score with tissue biochemistry using FTIR-LDA. Both systems are similar in their performance in predicting metastatic behaviour in tumours from individual patients.Citation
A correlation of FTIR spectra derived from prostate cancer biopsies with gleason grade and tumour stage. 2006, 50 (4):750-60; discussion 760-1 Eur. Urol.Journal
European UrologyDOI
10.1016/j.eururo.2006.03.031PubMed ID
16632188Type
ArticleLanguage
enISSN
0302-2838ae974a485f413a2113503eed53cd6c53
10.1016/j.eururo.2006.03.031
Scopus Count
Related articles
- Applications of Fourier transform infrared microspectroscopy in studies of benign prostate and prostate cancer. A pilot study.
- Authors: Gazi E, Dwyer J, Gardner P, Ghanbari-Siahkali A, Wade AP, Miyan J, Lockyer NP, Vickerman JC, Clarke NW, Shanks JH, Scott LJ, Hart CA, Brown M
- Issue date: 2003 Sep
- Should we replace the Gleason score with the amount of high-grade prostate cancer?
- Authors: Vis AN, Roemeling S, Kranse R, Schröder FH, van der Kwast TH
- Issue date: 2007 Apr
- Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens.
- Authors: Divrik RT, Eroglu A, Sahin A, Zorlu F, Ozen H
- Issue date: 2007 Sep-Oct
- Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
- Authors: Gofrit ON, Zorn KC, Taxy JB, Lin S, Zagaja GP, Steinberg GD, Shalhav AL
- Issue date: 2007 Nov
- Does prostate biopsy Gleason score accurately express the biologic features of prostate cancer?
- Authors: Stav K, Judith S, Merald H, Leibovici D, Lindner A, Zisman A
- Issue date: 2007 Sep-Oct